152 related articles for article (PubMed ID: 18413797)
1. Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.
Chen JS; Zhou LJ; Entin-Meer M; Yang X; Donker M; Knight ZA; Weiss W; Shokat KM; Haas-Kogan D; Stokoe D
Mol Cancer Ther; 2008 Apr; 7(4):841-50. PubMed ID: 18413797
[TBL] [Abstract][Full Text] [Related]
2. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Raynaud FI; Eccles SA; Patel S; Alix S; Box G; Chuckowree I; Folkes A; Gowan S; De Haven Brandon A; Di Stefano F; Hayes A; Henley AT; Lensun L; Pergl-Wilson G; Robson A; Saghir N; Zhyvoloup A; McDonald E; Sheldrake P; Shuttleworth S; Valenti M; Wan NC; Clarke PA; Workman P
Mol Cancer Ther; 2009 Jul; 8(7):1725-38. PubMed ID: 19584227
[TBL] [Abstract][Full Text] [Related]
3. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
[TBL] [Abstract][Full Text] [Related]
4. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.
Zhao HF; Wang J; Jiang HR; Chen ZP; To SS
J Exp Clin Cancer Res; 2016 May; 35():78. PubMed ID: 27176481
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
Djuzenova CS; Fiedler V; Memmel S; Katzer A; Sisario D; Brosch PK; Göhrung A; Frister S; Zimmermann H; Flentje M; Sukhorukov VL
BMC Cancer; 2019 Apr; 19(1):299. PubMed ID: 30943918
[TBL] [Abstract][Full Text] [Related]
6. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
Jiang Z; Pore N; Cerniglia GJ; Mick R; Georgescu MM; Bernhard EJ; Hahn SM; Gupta AK; Maity A
Cancer Res; 2007 May; 67(9):4467-73. PubMed ID: 17483362
[TBL] [Abstract][Full Text] [Related]
7. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
Bhattacharya B; Akram M; Balasubramanian I; Tam KK; Koh KX; Yee MQ; Soong R
Cancer Biol Ther; 2012 Jan; 13(1):34-42. PubMed ID: 22336586
[TBL] [Abstract][Full Text] [Related]
9. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
10. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
Filbin MG; Dabral SK; Pazyra-Murphy MF; Ramkissoon S; Kung AL; Pak E; Chung J; Theisen MA; Sun Y; Franchetti Y; Sun Y; Shulman DS; Redjal N; Tabak B; Beroukhim R; Wang Q; Zhao J; Dorsch M; Buonamici S; Ligon KL; Kelleher JF; Segal RA
Nat Med; 2013 Nov; 19(11):1518-23. PubMed ID: 24076665
[TBL] [Abstract][Full Text] [Related]
11. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
Liu Y; Cui B; Qiao Y; Zhang Y; Tian Y; Jiang J; Ma D; Kong B
Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
[TBL] [Abstract][Full Text] [Related]
12. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
[TBL] [Abstract][Full Text] [Related]
13. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P
Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
[TBL] [Abstract][Full Text] [Related]
15. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
16. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
17. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma.
Guillard S; Clarke PA; Te Poele R; Mohri Z; Bjerke L; Valenti M; Raynaud F; Eccles SA; Workman P
Cell Cycle; 2009 Feb; 8(3):443-53. PubMed ID: 19177002
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Raynaud FI; Eccles S; Clarke PA; Hayes A; Nutley B; Alix S; Henley A; Di-Stefano F; Ahmad Z; Guillard S; Bjerke LM; Kelland L; Valenti M; Patterson L; Gowan S; de Haven Brandon A; Hayakawa M; Kaizawa H; Koizumi T; Ohishi T; Patel S; Saghir N; Parker P; Waterfield M; Workman P
Cancer Res; 2007 Jun; 67(12):5840-50. PubMed ID: 17575152
[TBL] [Abstract][Full Text] [Related]
19. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
20. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Niedermeier M; Hennessy BT; Knight ZA; Henneberg M; Hu J; Kurtova AV; Wierda WG; Keating MJ; Shokat KM; Burger JA
Blood; 2009 May; 113(22):5549-57. PubMed ID: 19318683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
